STOCK TITAN

CLEVER LEAVES HLDGS WTS - CLVRW STOCK NEWS

Welcome to our dedicated page for CLEVER LEAVES HLDGS WTS news (Ticker: CLVRW), a resource for investors and traders seeking the latest updates and insights on CLEVER LEAVES HLDGS WTS stock.

Clever Leaves Holdings Warrants (CLVRW) is a Colombian company poised to become the largest grower and extractor in the cannabis industry by 2023. With over 10 million square feet of cultivation capacity, pharmaceutical-grade facilities, and a focus on low-cost operations, Clever Leaves is a pioneer in the medical cannabis field. The company's strategic approach, strong regulatory relationships, and experienced team position it as a leader in the global market.

Rhea-AI Summary

Clever Leaves Holdings (NASDAQ: CLVR, CLVRW) has signed a five-year agreement with Hypera Pharma to supply CBD-dominant oral solutions for Brazilian patients. This partnership aims to enhance accessibility to pharmaceutical-grade cannabis products, targeting various medical conditions. Hypera, a leading pharmaceutical company in Brazil, is recognized for its expertise in distribution and commercialization. The CBD products will be distributed through pharmacies and have been registered under the regulatory framework RDC 327. CEO Andres Fajardo emphasized that the collaboration aligns with Clever Leaves’ values and showcases their capacity to support the pharmaceutical industry's expansion into cannabis-based therapies. This move is positioned to leverage Brazil's prioritization of patient treatment and research, indicating potential for further product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

Clever Leaves has formed a partnership with Praetorian Global to cultivate premium medical cannabis from its GACP and GMP-certified facility in Colombia. This agreement allows Clever Leaves to enhance its product portfolio through advanced technology and exclusive genetics, with products expected to launch in Q2 2024 for global distribution, including the EU, UK, and Australia. Praetorian brings a genetic library recognized for high yield and efficiency, projected to expand its market presence across four continents by the end of 2023. The collaboration also aims to improve R&D efforts, providing a more diverse range of cannabis solutions for medicinal purposes. The partnership underscores Clever Leaves' commitment to innovation in the cannabis industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
none
-
Rhea-AI Summary

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a leading producer of pharmaceutical-grade cannabinoids, will present at the Sequire Cannabis & Psychedelics Conference on April 5, 2023, at 2:30 p.m. Eastern time. This virtual event will feature top speakers from the cannabis and psychedelic industries, which are projected to reach $72 billion annually by 2030. Interested parties can register for the event at this link. Clever Leaves aims to revolutionize cannabis production using sustainable methods and high-quality standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.73%
Tags
conferences
Rhea-AI Summary

On March 30, 2023, Clever Leaves reported a significant revenue increase, with fourth-quarter cannabinoid revenue rising 71% to $1.9 million and full-year cannabinoid revenue up 90% to $6.1 million. Total revenue for 2022 reached $17.8 million, a 16% year-over-year growth. The company has implemented cost reductions, achieving a 30% decrease in G&A and a notable 82% reduction in capital expenditures. However, net loss expanded to $66.2 million, driven by restructuring expenses and impairment charges. Looking ahead, Clever Leaves projects 2023 revenue between $19 million and $22 million and aims for adjusted EBITDA losses between $(13.6) million and $(10.6) million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
none
-
Rhea-AI Summary

On March 17, 2023, Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) announced the rescheduling of its conference call initially set for March 23, 2023, to discuss its fourth quarter and full year 2022 financial results. The call will now take place on March 30, 2023, at 5:00 p.m. ET, allowing more time to finalize the audit of the company's 2022 financial statements. A press release with the financial results will precede the call. The conference call will be open for questions following management’s presentation, with details available for both live participation and replay.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) has announced a conference call scheduled for March 23, 2023, at 5:00 p.m. Eastern time to discuss its Q4 and full-year results for 2022. The financial results will be released prior to the call. Interested parties can participate by dialing 1-855-238-2333 for toll-free access or 1-412-317-5222 for international calls, using Conference ID 10175028. A replay of the call will be available until March 30, 2023. Clever Leaves operates in Colombia, producing pharmaceutical-grade cannabinoids and aims to lead in sustainable cannabis production.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
none
Rhea-AI Summary

Clever Leaves has announced a strategic move to consolidate its cannabinoid operations exclusively in Colombia, ceasing all production in Portugal by Q1 2023. This decision is projected to yield approximately $7 million in cost savings by the end of 2023. The operational shift aims to leverage Colombia's cost efficiencies, with a cultivation capacity of over 1.8 million square feet and EU-GMP certifications. Despite incurring restructuring costs of $19 million to $21 million, the company expects this transition will enhance its competitiveness in the global medicinal cannabis market, while maintaining a focus on premium flower strains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
-
Rhea-AI Summary

Clever Leaves Holdings (Nasdaq: CLVR, CLVRW) reports a 12% increase in cannabinoid revenue year-over-year for Q3 2022, reaching $1.0 million. Total revenue fell to $3.3 million from $4.0 million due to inventory reductions in the non-cannabinoid segment. Gross profit was $0.3 million, with a significant $19.0 million impairment charge resulting in a net loss of $20.2 million. Adjusted EBITDA improved to $(5.4) million. The company revised its full-year revenue outlook to between $17.0 million and $17.7 million, down from $20-$25 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
-
Rhea-AI Summary

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) has received EU-GMP certification from INFARMED, I.P. for its Portugal facility, allowing for the production of cannabis dried flower for pharmaceutical use. This certification is essential for marketing medicinal cannabis products in Europe and represents a significant expansion opportunity for Clever Leaves. The company aims to meet stringent pharmaceutical standards, achieving certification in under 10 months. This milestone positions Clever Leaves to enhance revenue streams and support regional cannabis companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
Rhea-AI Summary

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) announced that its partner, Anden Naturals, has received sanitary registration for its THC dominant product, Andenol 50, from the Peruvian Health Authority. This marks the first THC product approved for commercialization in Peru. Andenol 50, a 5% THC oral solution, will be manufactured and packed by Clever Leaves in Colombia. The product aims to serve up to 30,000 registered patients in Peru, showcasing Clever Leaves' commitment to high-quality medical cannabis production.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
partnership

FAQ

What is the current stock price of CLEVER LEAVES HLDGS WTS (CLVRW)?

The current stock price of CLEVER LEAVES HLDGS WTS (CLVRW) is $0.025 as of July 18, 2024.

What makes Clever Leaves unique in the cannabis industry?

Clever Leaves is positioned to be the largest grower and extractor with a focus on pharmaceutical-grade facilities and low-cost operations.

What sets Clever Leaves apart from other Colombian license holders?

Clever Leaves stands out due to its strategic approach, strong regulatory relationships, and experienced team.

What are Clever Leaves' key capabilities in the medical cannabis industry?

Clever Leaves is developing key capabilities to win in the medical cannabis industry with its highly experienced team.

What is Clever Leaves' cultivation capacity by 2023?

Clever Leaves is set to have over 10 million square feet of cultivation capacity by 2023.

What is the status of Clever Leaves' production operations in Portugal?

Clever Leaves has ceased production operations in Portugal and is in the process of winding down these operations.

How can I contact Clever Leaves for press inquiries?

For press inquiries, you can contact Julian Wilches, Chief Regulatory Officer and Co-Founder, at +1-305-927-6642 or julian.wilches@cleverleaves.com.

When is the conference call for Clever Leaves' Third Quarter 2023 Summary?

The conference call will be held on Thursday, November 9, 2023, at 5:00 p.m. Eastern time.

Where can I find additional details about Clever Leaves' financial presentation?

You can refer to Clever Leaves' Form 10-Q for the fiscal period ended September 30, 2023, for additional details on the financial presentation.

What is the replay information for Clever Leaves' conference call?

The replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through November 16, 2023, at 1-844-512-2921.

What is Clever Leaves' position in the global market?

Clever Leaves is positioned to become a leader in the global market due to its differentiated business model and strong regulatory relationships.

CLEVER LEAVES HLDGS WTS

Nasdaq:CLVRW

CLVRW Rankings

CLVRW Stock Data

1.73M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TOCANCIPA - CUNDINAMARCA